Community Search

NOW AVAILABLE: Webcasts for the WPC 2013

Day 1: Wednesday, October 2, 2013

Day 2: Thursday, October 3, 2013

Day 3: Friday, October 4, 2013

Download the Final Program (including pre-congress sessions) 

What's the difference between plenary, parallel and workshops?
See session descriptions here.

View full faculty list 


Simultaneous translation into French

Session delivered in French


Wednesday, October 2, 2013

Day 1: 
Why and how specific neurons die in Parkinson’s disease and what can be done about it

Plenary Session 
Level of talks: Crosstalk

Learning Objectives:

1. To learn about new mechanisms of neurodegeneration of PD;
2. To understand the multifaceted nature of the neurodegenerative process in PD;
3. To acquire knowledge as to how basic science may help in treatment for PD.

Chair: Thomas Gasser (Germany)
Co-chair: Jon Stamford (UK)

Lecture 1: Propagation of the neurodegenerative process in PD and the Prion-like hypothesis

Speaker: Virginia Lee (USA) 

Lecture 2: Can the interaction between genetics, environment, and behavior be a key determinant of PD expression

Speaker: Christine Klein (Germany)

Lecture 3: What epidemiological and preclinical studies teach us about inflammation and PD

Speaker: Etienne Hirsch (France)

Lecture 4: Developing new treatments founded on the basic science of PD

Speaker: Patrik Brundin (USA)

Special Lecture

Introduction by Stanley Fahn (USA)


Lecture Title: The Life and Times of James Parkinson

Speaker: Gerald Stern


Lecture Title: The Glory of Canadian Sciences and Parkinson's Disease

Speaker: Rémi Quirion (Canada)

SESSION I -- 1:30PM – 3:00PM

Parallel Session: New genes and risk factors of PD

Level of talks: Moderately scientific

Learning Objectives:

1. To learn about new dominant and recessive high-penetrance PD genes as well as the newly discovered rare variants with moderate effect and their implication for the understanding of the biology of neurodegeneration in PD;
2. To learn about the role of common genetic risk-factors identified through GWAS, and their biological effects;
3. To learn about the latest developments that goes beyond pure genetic analysis and takes into account environmental factors, epigenetic modifications and clinical endophenotypes.

Chair: Christine Klein (Germany)
Co-chair: Matthew Farrer (Canada)

Lecture 1: New PD genes and rare variants

Speaker: Matthew Farrer (Canada)

Lecture 2: Risk factors for sporadic PD

Speaker: Andrew Singleton (USA)

Lecture 3: Genetics and gene environment interactions

Speaker: Haydeh Payami (USA)

Parallel Session: Protein misfolding as a key pathogenic event
Level of talks: Highly scientific

Learning Objectives:

1. To learn about the notion of protein folding and its role in pathological situations;
2. To understand the importance of the mechanisms responsible for the maintenance of the well-being of proteins;
3. To acquire knowledge about the link between defects in the lysosomal function and neurodegeneration.

Chair: Virginia Lee (USA)
Co-chair: Leonidas Stefanis (Greece)

Lecture 1: Alpha-synuclein conformation and neurodegeneration

Speaker: Leonidas Stefanis (Greece)

Lecture 2: Protein misfolding in neurodegenerative diseases

Speaker: Leonard Petrucelli (USA)

Lecture 3: Link between lysosomal function and neurodegeneration in PD

Speaker: Dimitri Krainc (USA)


Parallel Session: Role of functional imaging modalities in the diagnosis and management of PD

Level of talks: Crosstalk

Learning Objectives:

1. Learn about new advances in structural magnetic resonance (MR) imaging applied to PD, possible roles for diagnosis, differential diagnosis and biomarker;
2. Learn about neurochemical imaging using either PET or SPECT, role in diagnosis and as a biomarker to detect preclinical disease and measure disease progression;
3. Learn how studies of cerebral connectivity (fMRI, PET, DTI) can enhance our understanding of PD and of brain function.

Chair: Jon Stoessl (Canada)
Co-Chair: David Eidelberg (USA)

Lecture 1: Structural imaging for PD: MRI and transcranial sonography (TCS)

Speaker: Klaus Seppi (Austria)

Lecture 2: Neurochemical imaging

Speaker: Nicola Pavese (UK)

Lecture 3: Functional connectivity

Speaker: David Eidelberg (USA)


Parallel Session: Non-dopaminergic systems in PD: Anatomy, Biochemistry, and Pathology

Level of talks: Moderately scientific

Learning Objectives:

1. Understand how impairment in serotonin neuron function impacts the development of non-motor symptoms in PD;
2. Able to describe how cholinergic neuron dysfunction impacts the development of non-motor symptoms in PD and related disorders;
3. Explain the role of glutamatergic and serotonergic neurotransmission for the development of L-DOPA induced dyskinesias. 

Chair: Irene Litvan (USA)
Co-chair: Abdelhamid Benazzouz (France)

Lecture 1: Role of noradrenaline and serotonin systems for the development of non-motor symptoms

Speaker: Abdelhamid Benazzouz (France)

Lecture 2: Impact of cholinergic dysfunction on the development of non-motor symptoms

Speaker: Nicolaas Bohnen (USA)

Lecture 3: Role of non-dopaminergic systems in the development of L-DOPA-induced dyskinesias

Speaker: Angela Cenci (Sweden)


Workshop: Why supporting research is crucial: from government to private funding agencies

Level of talks: Crosstalk

Learning Objectives:

1.To understand the value of basic research in understanding causes of and finding treatments for PD;
2.To recognize the complementary roles of governmental agencies and non-governmental organizations in supporting basic research;
3.To provide examples of how the Parkinson’s community can effectively advocate for research funding.

Introduction: Tom Isaacs (UK)

Panelists: Etienne Hirsch (France), Rémi Quirion (Canada), Todd Sherer (USA), Amy Comstock Rick (USA)


Workshop: Mitochondrial defect in PD: myth or reality?

Level of talks: Crosstalk

Learning Objectives:

1. To learn about mitochondrial biology;
2. To understand the key issues that surrounds the question of mitochondrial defect in PD;
3. To participate in a discussion about whether or not at this point there are sound experimental elements to implicate a mitochondrial defect in PD pathogenesis.

Overview: Mitochondria: a multifunctional organelle

Speaker: Carolyn Sue (Australia)

Case presentations: The status of mitochondria in PD

Panelists: Carolyn Sue (Australia), Charleen Chu (USA) & Miquel Vila (Spain)


Workshop: Sexual issues in Parkinson's disease: assessment and intervention

Level of talks: Crosstalk

Learning Objectives:

1. Describe the variety of sexual disorders among patients with Parkinson’s disease;
2. Appreciate the range of therapeutic interventions for the various sexual disorders in Parkinson’s disease;
3. Understand that having Parkinson's disease and being intimate are not mutually exclusive.

Overview: Sexual challenges in Parkinson’s and therapeutic options

Speaker: Paul Rabstyzn (Netherlands)

Case Presentations:

Panelists: Gila Bronner (Israel) & Paul Rabstyzn (Netherlands)


Workshop: Quality of life and comfort in the late stages of Parkinson's disease

Level of talks: Crosstalk

Learning Objectives:

1. Explore the symptoms of late stage and end stage Parkinson’s;
2. Understand the medical, ethical and legal issues;3. Learn about the Palliative Care model, helpful in maintaining comfort for patient/family.

Overview: Issues and choices in late stage Parkinson’s

Speaker: Janis Miyasaki (Canada)

Case Presentations

Panelists: Lisa Mann (USA) and Janis Miyasaki (Canada) 

French Track  

Level of talks: Crosstalk in French

Chair: Serge Przedborski (USA)

Lecture 1:
Is there a functional defect with mitochondrial in Parkinson’s disease?

Speaker: Celine Perier (France)

Lecture 2: Clinical Trials: Present challenges and emerging breakthroughs

Speaker: Olivier Rascol (France)


SESSION II - 3:30PM – 5:00PM

Parallel Session: Quality of life in Parkinson’s disease: several important determinants
Level of talks: Crosstalk

Learning Objectives

1. Define obstacles people face after diagnosis through the continuum of the disease;
2. Understand practical solutions and methods of achieving overall quality of life;
3. Understand the power of engagement and advocacy in dealing with psychological challenges of PD.

Chair: Alessandro Di Rocco (USA)

Co-chair: Peter Fletcher (UK)

Lecture 1: Practical solutions to driving, early job loss, and relationship issues

Speaker: Peter Fletcher (UK)

Lecture 2: Psychological solutions to dealing with pity, dignity, sense of worth and communication

Speaker: Diane Cook (USA)

Lecture 3: Physical solutions to coping with pain, motor/non-motor, cognition, mood, and behavior

Speaker: Soania Mathur (Canada)

Parallel Session: How Parkinson’s affects attention and memory

Level of talks: Crosstalk

Learning Objectives:

1. Describe the clinical features, syndromes, and proposed mechanisms of cognitive dysfunction in Parkinson’s disease;
2. List and contrast the various approaches for evaluating and monitoring the progression and treatment of cognitive dysfunction in Parkinson’s disease, including assessments that can take place during a clinical interview, using bedside; screening tools, and in performance-based tests;
3. Initiate practical strategies for management of cognitive deficits in Parkinson’s disease.

Chair: Alexander Tröster (USA)
Co-Chair: Connie Marras (Canada)

Lecture 1: Memory and attention issues in Parkinson’s disease—clinical characteristics and mechanisms

Speaker: David Burn (UK)

Lecture 2: Clinical Assessment of Cognition in PD

Speaker: Connie Marras (Canada)

Lecture 3: Practical management of cognitive deficits in Parkinson's disease; what can occupational therapists offer?

Speaker: Margarita Makoutonina (Australia)

Parallel Session: Experimental models of non-motor manifestations of PD

Level of talks: Moderately scientific

Learning Objectives:

1. Describe animal models of non-motor manifestation in Parkinson’s disease;
2. Compare the non-motor symptoms in Parkinson’s disease and animal models;
3. Identify the neuronal network involved in the genesis of non-motor symptoms in Parkinson’s disease.

Chair: Beth-Anne Seiber (USA)
Co-Chair: Ingrid Philippens (Netherlands)

Lecture 1: Animal models of hyper dopaminergic behavior in Parkinson’s disease

Speaker: Christelle Baunez

Lecture 2: Animal models of sleep disorders in Parkinson’s disease

Speaker: Ingrid H Philippens (Netherlands)

Lecture 3: Animal models of gastrointestinal dysfunction in Parkinson’s disease

Speaker: Marie-Françoise Chesselet (USA)


Parallel Session: Optogenetic tools to study PD pathophysiology

Level of talks: Highly scientific

Learning Objectives:

1. To understand the power and use of Optical Neural Engineering to probe neural function;
2. To describe how neural activity shapes motor behavior;
3. To be able to discuss how neural activity controls motor behavior.

Chair: Ted Dawson (USA)
Co-Chair: Antoine Adamantidis (Canada)

Lecture 1: Optical Neural Engineering

Speaker: Antoine Adamantidis (Canada)

Lecture 2: Regulation of Parkinsonian motor behaviors by optogenetic control of basal ganglia circuitry

Speaker: Anatol Kreitzer (USA)

Lecture 3: Optical Interrogation of the dopaminergic systems

Speaker: Antonello Bonci (USA)


Workshop: Everything you always wanted to know about genetics and that you never dared to ask

Level of talks: Crosstalk

Learning Objectives:

1. To understand the basic principles of Mendelian genetics;
2. To learn about the genetic contribution to Parkinson’s disease;
3. To recognize the familial significance of genetics on Parkinsonisms.

Overview: What is genetics?

Speaker: Carolyn Sue (Australia)

Case Presentations:

Panelists: Susan Bressman (USA), Carolyn Sue (Australia), Matthew Farrer (Canada) and Andrew Singleton (USA)


Workshop: How researchers and people with Parkinson’s can advance clinical trials together

Level of talks: Crosstalk

Learning Objectives

1. To learn about opportunities where people with Parkinson's can learn about and be trained as clinical research advocates.
2. To understand the key issues that people with Parkinson's should be aware of and questions they should be asking when evaluating a clinical trial and where or not to participate
3. To understand that there are steps people with Parkinson's can take to influence and improve the clinical trial process


Speaker: Linda Morgan (USA)

Panel Discussion:

Panelists: Tom Isaacs (UK, Steve DeWitte (USA) & Linda Morgan (USA)

Workshop: How drugs make it to your cabinet

Level of talks: Crosstalk

Learning Objectives

1. Understand the process of drug discovery and resources needed to bring drugs to patients’ cabinets
2. Understand translational research (from the bench to the bedside);
3. Be able to explain the pre-clinical and clinical phases of drugs and the important role of the Parkinson community in pushing these phases forward.


Overview: Innovations in neuroscience technologies as they apply to finding target molecules to the point of pre-clinical studies

Speaker: Howard Federoff (USA)

Panel Discussion:

Panelists: Marc Brinkman (Germany) and Howard Federoff (USA)


Workshop: Music, art, creativity and Parkinson's
Level of talks: Crosstalk

Learning Objectives:

1. To understand how people with Parkinson’s have integrated high-quality performing and visual arts into their Parkinson’s outreach and support programs;
2. To explore effective common Best Practices in singing, visual art, and dance programs that have worked particularly well in engaging persons with PD, care partners and families;
3. Understand methods and barriers to building arts-based programs.


Overview: Creativity and Parkinson’s

Speaker: Steven Frucht (USA)

Panel discussion:

Panelists: Steven Frucht (USA), Margaret Mullarney (Ireland), David Simmonds (Canada)

French Track  

Level of talks: Crosstalk in French

Chair: David Lussier (Canada)

Lecture 1: Is there a role for gene- and cell-based therapies in the treatment of Parkinson disease?

Speaker: Stephane Palfi (France)

Lecture 2: Sleep, fatigue and apathy in Parkinson's disease

Speaker: Nico Diederich (Luxembourg)

Meet the Experts 

Level of talks: Crosstalk

Note: Seats at tables are limited. Ticket required.

Table 1: Speech Pathology and Parkinson’s

    Host: Lorraine Ramig (USA)

Table 2: Physical therapy and Parkinson’s - can it really help?

    Host: Terry Ellis (USA)

Table 3: Blogging and Parkinson's: How people with Parkinson's can educate and raise awareness via blogging

    Co-hosts: Bob Kuhn (Canada) & Jean Burns (USA)

Table 4: What to Ask Before Joining a Clinical Trial: PwP to PwP

    Co-hosts: Jon Stamford (UK) & Israel Robledo (USA)

Table 5: Young Onset Parkinson’s: Unique Challenges

    Host: Peter Davison (Canada)

Table 6: Psychiatric Changes in Parkinson's Disease

    Host: Laura Marsh (USA)

Table 7: Sex & Parkinson's disease

    Host: Gila Bronner (Israel)

Table 8: What's in the pipeline for new delivery systems for Parkinson's?

    Host: Angelo Antonini (Italy)

Table 9: Facing your fear: Rising to the Challenge

    Host: Alex Flynn (UK) & Daniel Weintraub (USA)


Wrap-Up 5:15PM – 6:30PM    

Facilitator: David Iverson (USA)

Ted Dawson (USA), Andres Lozano (Canada), Mark Guttman (Canada), Susan Fox (Canada)



Day 2:
Non-motor manifestations of Parkinson’s disease

Plenary Session 

Level of talks: Crosstalk

Learning Objectives:

1. Better understand the diversity of non-motor symptoms that can be present in PD and analyze their clinical features;
2. Recognize the role of imaging studies in the assessment and understanding of non-motor manifestations of PD;
3. Be able to describe how co-existent medical conditions or co-morbidities may have an impact on the clinical features and the progression of PD.

Chair: Oscar Gershanik (Argentina)
Co-chair: Sharon Daborn (Australia)

Lecture 1: The spectrum of non-motor symptoms in PD

Speaker: Ray Chaudhuri (UK)

Lecture 2: Dementia and psychiatric manifestations in PD

Speaker: David Burn (UK)

Lecture 3: Contribution of functional neuroimaging to the understanding of non-motor manifestations of PD

Speaker: Antonio Strafella, (Canada)

Lecture 4: The impact of other medical conditions on the course of PD

Speaker: Janis Miyasaki (Canada)

WPC James Parkinson Lecture 

Introduction by: Jon Stoessl (Canada)

Presentation Title: Past, Present and Future of Parkinson Disease

Speaker: Warren Olanow (USA)

SESSION I -- 1:30PM - 3:00PM

Parallel Session: PD or not PD - that is the question: Is it time to redefine/reclassify Parkinson’s disease?

Level of talks: Crosstalk

Learning Objectives:

1. Discuss the current definitions and diagnostic criteria for PD and the reasons for redefining the disorder;
2. Discuss "prodromal" Parkinson's disease and monogenetic Parkinson's disease and how these challenge approaches to classification and diagnosis;
3. Discuss considerations and challenges to establishing new diagnostic criteria for PD.

Chair: Christopher Goetz (USA)
Co-chair: Daniela Berg (Germany)

Lecture 1: Current definitions and diagnostic criteria: reasons for redefining the disorder.

Speaker: Joaquim Ferreira (Portugal)

Lecture 2: The challenge of "prodromal" Parkinson's disease

Speaker: Ron Postuma (Canada)

Lecture 3: Redefining Parkinson's disease: possible approaches to developing new diagnostic criteria

Speaker: Daniela Berg (Germany)

Parallel Session:
Hallucinations and related phenomena in PD

Level of talks: Crosstalk

Learning Objectives:

1. Participants should be able to describe the range of psychotic phenomenon in PD;
2. Identification of factors associated with the pathogenesis and progression of PD psychosis;
3. Discuss evidence based medicine recommendations and integrated treatment options in the management of PD psychosis.

Chair: Ronald Pfeiffer (USA)
Co-chair: Regina Katzenschlager (Austria)

Lecture 1: Prototypical and less common hallucinations

Speaker: Regina Katzenschlager (Austria)

Lecture 2: Where is the nucleus hallucinatorius and how it gets stimulated?

Speaker: Nico Diederich (Luxembourg)

Lecture 3: Management of hallucinations and related symptoms

Speaker: Daniel Weintraub (USA)

Parallel Session: Mitochondrial quality control mechanisms

Level of talks: Highly scientific

Learning Objectives:

1. Understand the surveillance mechanisms acting at the molecular, organelle, and cellular levels that monitor mitochondrial integrity and ensure the maintenance of mitochondrial proteostasis;
2. Identify the molecular mechanisms by which Pink1 and Parkin regulate the selective removal of impaired mitochondria by autophagy;
3. Recognize the molecular machinery responsible for mitochondrial fusion/fission and cristae morphology and understand how alterations in these pathways can impair mitochondrial trafficking and distribution and lead to neurodegeneration.

Chair: Edward Fon (Canada)
Co-chair: Charleen Chu (USA)

Lecture 1: Mitochondrial quality control- a matter of life and death for neurons

Speaker: Heidi M. McBride (Canada)

Lecture 2: Mechanisms of mitophagy in Parkinson’s disease

Speaker: Charleen Chu (USA)

Lecture 3: Mitochondrial remodeling in the control of apoptosis

Speaker: Luca Scorrano (Switzerland)

Parallel Session: Ways for people with Parkinson’s to become empowered

Level of talks: Crosstalk

Learning Objectives:

1. To provide a broad perspective on different aspects and definitions of "patient empowerment” explaining what it really means to be empowered;
2. Understand ways that empowered patients can inform the body of knowledge on what it’s like living with a chronic disease and how this influence matters;
3. Understand ways how patient empowerment can be achieved.

Chair: Joyce Gordon (Canada)
Co-chair: Fulvio Capitanio (Spain)

Lecture 1: Why and how people with Parkinson’s need empowerment - Finding your own niche

Speaker: Fulvio Capitanio (Spain)

Lecture 2: Evidence-based self-management practices

Speaker: Patrick McGowan (Canada)

Lecture 3: Increasing Parkinson’s advocacy effectiveness with lessons learned from other diseases

Speaker: Christine Albee (Canada)

Workshop: Benefits and risks of genetic testing

Level of talks: Crosstalk

Learning Objectives:

1. To learn about the different techniques and resources available to test for genetic defects;
2. To understand the implications of knowing and not-knowing that one carries a mutation;
3. To appreciate who and when might benefit from genetic testing.


Introduction: Overview of genetic testing

Speaker: Oksana Suchowersky (Canada)

Case Presentations:

Panelists: Oksana Suchowersky (Canada), Susan Bressman (USA), Nathalie Bolduc (Canada)

Workshop: Sleep and fatigue in PD

Level of talks: Crosstalk

Learning Objectives:

1. To review the epidemiology and natural history of sleep disorders and fatigue in PD;
2. To review validated tools for measuring fatigue and diagnosing sleep disorders;
3. To review possible treatment modalities, both pharmacological and non-pharmacological.

Introduction: Overview of sleep, sleepiness and fatigue in PD

Speaker: Joseph H Friedman (USA)

Case Presentations: Tips to dealing with sleeplessness and fatigue

Panelists: Joseph Friedman (USA) and Cathi A. Thomas (USA)

Workshop: Ethical dilemmas posed by new diagnostic and therapeutic technologies

Level of talks: Crosstalk

Learning Objectives

1. To acquire the basis of ethics;
2. To learn, through case presentations, about the types of ethical issues;
3. To better understand rational justification for ethical decisions.


Introduction: Overview of ethics in medicine

Speaker: John Loike (USA)

Panel discussion:

Panelists: John Loike (USA), Hubert Fernandez (USA), Jon Stamford (UK) and Karl Friedl (USA)

Workshop: Tricks of the trade: clever strategies to improve mobility

Level of talks: Crosstalk

Learning Objectives:

1. Explore clever strategies to overcome challenges to daily mobility (suggestions from professional and PWPs);
2. Demonstrate the integration of strategies to improve mobility into daily life (videos, live demonstrations);
3. Discuss potential mechanisms underlying strategy effectiveness.

Introduction: Overview of Idea Behind Strategies for improving mobility

Speaker: Terry Ellis (USA)

Panel discussion:
Panelists: Terry Ellis (USA), Mariella Graziano (Luxembourg), Samyra Keus (Netherlands), Pam Quinn (USA)

French Track 

(Learn more about the french track)

Level of talks: Crosstalk in French

Chair: Michel Panisset (Canada) 

Lecture 1: Advances in the genetics of Parkinson’s disease

Speaker: Nicolas Dupré (Canada)

Lecture 2: The experimental models of Parkinson’s disease: Are they useful?

Speaker: Marie-Francoise Chesselet (USA)

SESSION II - 3:30PM- 5:00PM


Parallel Session: PD or look-alikes: how to diagnose them and what are their long-term prognoses?

Level of talks: Crosstalk

Learning Objectives:

1. To learn how to diagnose and differentiate drug-induced parkinsonism from PD and discuss its long-term prognosis;
2. To learn how to diagnose and differentiate progressive supranuclear palsy from PD and discuss its long-term prognosis;
3. To learn how to diagnose and differentiate multiple system atrophy from PD and discuss its long-term prognosis.

Chair: Joseph Jankovic (USA)
Co-chair: Irene Litvan (USA)

Lecture 1: Drug Induced Parkinsonism

Speaker: Stewart Factor (USA)

Lecture 2: PD or progressive supranuclear palsy

Speaker: Irene Litvan (USA)

Lecture 3: PD or Multiple system atrophy

Speaker: Cheryl Waters (USA)

Parallel Session: Clinical trial outcomes—What do they really mean?

Level of talks: Moderately scientific

Learning Objectives:

1. Understand the complexities of measuring outcomes of clinical trials;
2. Be familiar current trials for PD;
3. Learn about the placebo effect and its consequences on clinical trials.

Chair: Olivier Rascol (France)
Co-Chair: Cristina Sampaio (USA)

Lecture 1: Clinical trial endpoints in PD – What is really meaningful?

Speaker: Cristina Sampaio (USA)

Lecture 2: The placebo effect: how it complicates clinical trial results

Speaker: Christopher Goetz (USA)

Lecture 3: Slowing clinical progression in PD –can it be proven in clinical trials?

Speaker: Fabrizio Stocchi (Italy)

Parallel Session: The search for new delivery methods for drugs

Level of talks: Crosstalk

Learning Objectives:

1. Understand the relevance of continuous drug delivery for PD;
2. Become familiar with recent developments in the field of oral and non-oral drug delivery;
3. Critically discuss the potential role of gene therapy in the field of PD.

Chair: David Brooks (UK)

Co-chair: TBD

Lecture 1: Improving oral drug delivery in PD – recent advances

Speaker: TBD

Lecture 2: Infusion therapies and other non-oral routes of drug delivery

Speaker: Angelo Antonini (Italy)

Lecture 3: Delivering therapeutic genes into the brain – a future way of drug delivery?

Speaker: Stephane Palfi (France)


Parallel Session: Is PD an axonopathy?

Level of talks: Highly scientific

Learning Objectives:

1. Understand the pathological findings supporting the presence of axonopathy in PD;
2. Understand evidence for primary synaptic pathology in PD and its implication for treatment;
3. Understand evidence and implications for altered axonal transport in PD.

Chair: Maria Spillantini (UK)
Co-chair: Sreegana Chandra (USA)

Lecture 1: Pathological evidence for axonopathy in Parkinson’s disease

Speaker: Dennis Dickson (USA)

Lecture 2: Evidence for synaptic dysfunction in Parkinson’s disease

Speaker: Sreegana Chandra (USA)

Lecture 3: Alterations in axonal transport in Parkinson’s disease

Speaker: Scott Brady (USA)



Workshop: Choosing a care facility: When is it time? What are the options?

Level of talks: Crosstalk

Learning Objectives:

1. Learn when it is time to consider a care facility and what are the alternatives;
2. Explore models of informed care from around the world that maximize comfort, care and activity for Parkinson patients;
3. Learn the challenges and successful approaches used to advocate for systems that meet the specific needs of PD patients.

Introduction: Overview of Care Models and Options

Speaker: Elaine Book (Canada)

Case Presentation: Global Care Models

Panelists: Maria Barretto (India), Marten Munneke (Netherlands), Ruth Hagestuen (USA)


Workshop: Do experimental models of Parkinson’s disease predict treatment outcome?

Level of talks: Moderately scientific

Learning objectives:

1. To learn about the main experimental models of PD;
2. To understand the key challenges between the preclinical and clinical studies;
3. To participate in a discussion about potential remedy.


Speaker: Anthony Lang (Canada)

Panel discussion:

Panelists: Anthony Lang (Canada), Serge Przedborski (USA), Etienne Hirsch (France), Ted Dawson (USA)


Workshop: Complementary and integrative medicine

Level of talks: Crosstalk

Learning objectives:

1. Learn about the fields of alternative, complementary and integrative medicines;
2. Recognize the art and the science of these therapies;
3. Understand the categories of integrative medicine/complementary and alternative medicines, including a discussion of the scientific evidence, the risks, the potential benefits and the future of those therapies most commonly used by the PD community.

Introduction: Insights into Complementary Therapies

Speaker: Monique Giroux (USA)

Panel discussion: The Art and the Science of Complementary Therapies

Panelists: Monique Giroux (USA), Louis Tan (Singapore), Angela Robb (USA)


Workshop: Dance and Parkinson’s: Why and How?

Level of talks: Crosstalk

Learning Objectives:

1. Describe the research evidence supporting the benefits of dance in PD;
2. Describe the essential elements of dance thought to mediate improvements in function;
3. Discuss ways to incorporate dance into your life: community based models

Overview: How do we know dance helps people with Parkinson’s?

Speaker: Gammon Earhart (USA)

Panel discussion: Let’s dance! Showing the results of movement

Panelists: Gammon Earhart (USA), David Leventhal (USA), Maura Fisher (Canada), JoanAbbey Sack (Canada), Diane Côté (Canada)


French Track 

(Learn more about the french track)

Level of talks: Crosstalk in French

Chair: Anne-Louise Lafontaine (Canada)

Lecture 1: The problem of the accumulation of toxic proteins and the significance of the quality control mechanisms in Parkinson’s disease

Speaker: Edward Fon (Canada)

Lecture 2: Non-motor manifestations of Parkinson’s disease

Speaker: Sylvain Chouinard (Canada)


Roundtable: Meet the Experts
Level of talks: Crosstalk

Table 1: DBS: A Team Effort

    Co-hosts: Elena Moro (France) & David Simmonds (Canada)

Table 2: Effective Fundraising Models for PwP founded non-profit organizations: How to survive

    Hosts: Fulvio Capitanio (Spain) & Tom Isaacs (UK)

Table 3: Non-motor Symptoms & PD

    Host: Ronald Pfeiffer (USA)

Table 4: Genetic Testing & PD: What questions you should be asking

    Host: Susan Bressman (USA)

Table 5: Parkinson’s disease and cancer (repeated on Friday)

Rivka Inzelberg (Israel)

Table 6: Staying engaged and raising children after a Parkinson’s diagnosis

    Co-hosts: Soania Mathur (Canada) & Sharon Daborn (Australia)

Table 7: Parkinson’s disease & women

    Co-hosts: Claire Henchcliffe (USA) & Sara Riggare (Sweden)

 Table 8: Flying solo - living alone with Parkinson's

    Co-hosts: Ryan Tripp (Canada) & Cathi Thomas (USA)

Table 9: Service dogs and Parkinson's: Everything you need to know

    Co-hosts:  Carolyn Weaver (USA) & Renee Le Verrier (USA)


Wrap-Up 5:15PM – 6:30PM

Facilitator: David Iverson (USA)

Panelists: Anthony Lang (Canada), Kapil Sethi (USA), Joseph H Friedman (USA), Janis Miyasaki (Canada), David Brooks (UK), Alex Tröster (USA)

Friday, October 4, 2013

Day 3:
New Views on the Management of Parkinson’s disease

Plenary Session 

Level of talks: Crosstalk

Learning Objectives:

1. Appreciate the experimental developments and current clinical applications of cell and gene-based technologies;
2. Learn about non-medical interventions, including lifestyle activities, self-management and empowerment aspects;
3. Understand the pros and cons of a multidisciplinary treatment approach.

Chair: Eduardo Tolosa (Spain)
Co-Chair: Alice Templin (Canada)

Lecture 1: Cell and gene-based technologies for restorative and neuroprotective therapies

Speaker: Roger Barker (UK)

Lecture 2: Exercise, diet, and other lifestyle activities as treatments for Parkinson disease

Speaker: Marten Munneke (Netherlands)

Lecture 3: Empowered patients and how they can help improve healthcare.

Speaker: Dave de Bronkhart (USA)

Lecture 4: Roles for healthcare professionals: multidisciplinary care for Parkinson disease.

Speaker: Nir Giladi (Israel)

Special Lecture: Living Positively After a Diagnosis of Parkinson's

Introduction by: Robin Elliott (USA)

Speaker: Rich Clifford (USA), Soania Mathur (Canada) & Alex Flynn (UK)

SESSION I – 1:30PM – 3:00PM

Parallel Session: Update on Gaucher and Parkinson's diseases

Level of talks: Crosstalk

Learning Objectives:

1. Understand the connection between mutations that cause Gaucher disease and PD;
2. To acquire knowledge about the link between Gaucher’s disease and synucleinopathies;
3. To understand how treatments developed for Gaucher disease may be beneficial in PD.

Chair: Susan Bressman (USA)
Co-chair: Pablo Sardi (USA)

Lecture 1: What is new about the link between Gaucher mutations and Parkinsonism

Speaker: Roy Alcalay (USA)

Lecture 2: Exploring mechanisms that underlie between mutations in Gaucher disease gene and synucleinopathy risk

Speaker: Michael Schlossmacher (Canada)

Lecture 3: How the understanding of Gaucher could lead to new therapies for Parkinson's

Speaker: Pablo Sardi (USA)

Parallel Session: New insights into Parkinson's disease from experimental cell- and gene-based strategies

Level of talks: Highly Scientific

Learning Objectives

1. Learn about recent developments in the use of human embryonic stem cells, and induced pluripotent stem cells, to generated dopamine neurons for cell replacement in PD;
2. Learn about two novel strategies to modify disease progression in PD based on insights in neurotrophic factor signalling;
3. Learn about the role of the role of the developmental transcription factor Nurr1 as a mediator of neurodegeneration in PD.

Chair: Roger Barker (UK)
Co-chair: Mickael Decressac (Sweden)

Lecture 1: Use of human ES and iPS cells for cell replacement in Parkinson´s disease.

Speaker: Malin Parmar (Sweden)

Lecture 2: Role of Sonic hedgehog in maintaining striatal homeostasis

Speaker: Andreas Kottmann (USA)

Lecture 3: Nurr1 as a therapeutic target for neuroprotection and disease modification in PD

Speaker: Mickael Decressac (Sweden)


Parallel Session: Neurobiology and treatment of dyskinesias

Level of talks: Moderately scientific

Learning Objectives:

1. Increase the knowledge on the various neurotransmitters implicated in L-DOPA induced dyskinesia describing their possible interactions;
2. Provide a broad perspective of the novel therapeutic strategies emerging from preclinical studies utilizing experimental models of PD;
3. Increase the understanding of the role of both short and long term synaptic mechanisms implicated in the motor and behavioral complications of chronic L-DOPA therapy.

Chair: Karl Friedl (USA)
Co-chair: Erwan Bezard (France)

Lecture 1: Maladaptive plasticity in L-DOPA-induced dyskinesia: emerging role of serotonin transmission and other presynaptic factors

Speaker: Angela M. Cenci (Sweden)

Lecture 2: Pre- and post-synaptic molecular mechanism underlying L-DOPA-induced dyskinesia as possible new pharmacological targets

Speaker: Erwan Bezard (France)

Lecture 3: Multiple dopamine-dependent synaptic mechanisms underlying dyskinesia in animal models

Speaker: Barbara Picconi (Italy)


Parallel Session: Pathophysiology and management of head drop and bent spine in PD: Are they dystonia or myopathy or both?

Level of talks: Moderately scientific

Learning objectives:

1. To learn current understanding of the mechanism of dropped head and bent back in PD
2. To learn how to differentiate similar condition with different etiology
3. To learn current management of dropped head and bent back

Chair: Ryuji Kaji (Japan)

Co-chair: Simone Spuler (Germany)

Lecture 1: Myopathy causing camptocormia in idiopathic Parkinson's disease

Speaker: Simone Spuler (Germany)

Lecture 2: Camptocormia: pathogenesis, classification, and response to therapy

Speaker: Joseph Jankovic (USA)

Lecture 3: Dropped head syndrome in Parkinson's disease

Speaker: Kenichi Kashihara (Japan)


Workshop: What you need to know about DBS: Selection, side effects, and new device development

Level of talks: Moderately scientific

Learning objectives

1. To provide an interactive educational program focusing on the latest advances in and the practical aspects of deep brain stimulation for Parkinson’s disease;
2. To discuss rationale for selection of patients, targets, devices, and stimulation parameters;
3. To review the potential risks and how to minimize the potential long-term effects and complications related to deep brain stimulation.

Overview: Deep brain stimulation

Speaker: Michael Okun (USA)

Case presentations

Panelists: Michael Okun (USA) and Elena Moro (France)


Workshop: Is PD an accelerated form of aging?

Level of talks: Crosstalk

Learning Objectives:

1. To learn the selective vulnerabilities seen in PD and normal aging;
2. To understand the function and electrophysiological changes seen in PD and normal aging;
3. To be able to discuss new models of normal aging and illustrate their relevance to PD.

Overview: Aging and PD

Speaker: Timothy J. Collier (USA)

Panel discussion: The implication of cell function in determining differential vulnerabilities

Panelists: James Surmeier (USA) and Timothy Collier (USA)


Workshop: Pain in PD
Level of talks: Crosstalk

Learning Objectives:

1. To gain an understanding of the multifaceted nature of pain syndromes in PD;
2. To understand the neurophysiological substrate of pain in PD;
3. To develop a practical approach to the management of pain in PD.

Overview: Pain in PD

Speaker: Blair Ford (USA)

Panel discussion: A practical and clinical approach to treating pain in PD

Panelists: David Lussier (Canada) and Blair Ford (USA)


Workshop: Speech and Parkinson’s

Level of talks: Crosstalk

Learning objectives:

1. To gain an understanding of the complex skills needed for effective speech production as shown through recent evidence;
2. Understand the best approaches to deal with the voice, speech, and language changes of PD over the course of the illness and most effective interventions;
3. To learn best practice Speech Language Pathology interventions and options for treatment in the early, middle and late stages of Parkinson’s.

Overview: Models of care on speech for people with Parkinson’s

Speaker: Angie Roberts-South (Canada)

Case Presentations:

Panelists: Angie Roberts-South (Canada), Lorraine Ramig (USA) & Bonnie Bereskin (Canada)


French Track  

(Learn more about the french track)
Level of talks: Crosstalk in French

Chair: Sylvain Chouinard (Canada)

Lecture 1: Is there a link between Parkinson’s disease and the Gaucher metabolic disorder?

Speaker: Guy Rouleau (Canada)

Lecture 2: How imaging technologies can inform about the brain function in Parkinsonian patients

Speaker: Alain Dagher (Canada)

SESSION II – 3:30 – 5:00PM

Parallel Session: Freezing and falls

Level of talks: Crosstalk

Learning Objectives:

1. Describe the potential mechanisms underlying freezing of gait and the role of cueing in reducing freezing;
2. Describe the mechanisms underlying falling and the evidence on the modifiability of postural control deficits in PD;
3. Discuss the evidence on the benefits of exercise in reducing falling in PD.

Chair: Nir Giladi (Israel)
Co-chair: Alice Nieuwboer (Belgium)

Lecture 1: Freezing- Underlying mechanisms and the role of cueing

Speaker: Alice Nieuwboer (Belgium)

Lecture 2: Why do persons with PD fall? Does treatment help to reduce falling?

Speaker: Fay Horak (USA)

Lecture 3: The benefits of exercise in reducing falling in PD

Speaker: Victoria Goodwin (UK)


Parallel Session: Promising approaches to identify and validate biomarkers
Level of talks: Crosstalk

Learning Objectives:

1. To learn about disease signatures and markers;
2. To appreciate the array of techniques available to search for biomarkers;
3. To be informed about new and promising biomarkers for PD.

Chair: Kapil Sethi (USA)

Co-chair: David Standaert (USA)

Lecture 1: What are biomarkers and why do we need them?

Speaker: David Standaert (USA)

Lecture 2: Update on unbiased methodologies to identify biomarkers

Speaker: Howard Federoff (USA)

Lecture 3: Emerging biomarkers

Speaker: Claire Henchcliffe (USA)

Parallel Session: Drug development challenges: from the pharmaceutical industry, bioethics, and patient advocacy perspective
Level of talks: Crosstalk

Learning Objectives:

1. To understand the challenges to drug development from a variety of perspectives;
2. Appreciate the difficult course of drug development from the bioethics perspective;
3. Understand the role of patient advocates in drug development.

Chair: Marc Brinkman (Germany)
Co-chair: Bernard Ravina (USA)

Lecture 1: Drug development challenges - Pharmaceutical industry perspective

Speaker: Bernard Ravina (USA)

Lecture 2: Drug development challenges - A bioethics perspective

Speaker: Spencer Hey (Canada)

Lecture 3: Drug development challenges - Patient advocacy perspective

Speaker: Tom Isaacs (UK)


Parallel Session: How should levodopa induced dyskinesia be managed today?

Level of talks: Crosstalk

Learning objectives:

1. To understand the subtypes of levodopa induced dyskinesias (LID) in Parkinson Disease (PD);
2. Be able to evaluate and assess severity of dyskinesia in patients with LID;
3. Understand how to prevent and manage levodopa-induced dyskinesia.

Chair: Kailash Bhatia (UK)
Co-chair: Jose Obeso (Spain)

Lecture 1: Recognizing the subtypes and assessing severity of dyskinesia and the clinical impact

Speaker: Beom S. Jeon (South Korea)

Lecture 2: Current management of LID – medical and surgical

Speaker: Jose Obeso (Spain)

Lecture 3: Future Management of LID: What’s in the pipeline?

Speaker: Susan Fox (Canada)

 [Supported by Adamas Pharmaceuticals]

Workshop: The role of people with Parkinson's in the research process: How are they prepared and what can they do?

Level of talks: Crosstalk 

Learning Objectives:

1. To understand how engaging people with Parkinson's informs the research process;
2. Be able to list ways to engage PwPs in the research process;
3. Understand how to improve communication between researchers and research participants in clinical trials.

Introduction: Overview of the research process and advances in communication between researchers and participants

Speaker: Diane Cook (USA)

Panel discussion:

Panelists: Benzi Kluger (USA) (Researcher), Diane Cook (USA), Veronica Todaro (USA), Claire Meunier (USA)

Workshop: Which physical and mental exercises are good for people with Parkinson’s?

Level of talks: Crosstalk

Learning objectives:

1. Understand the physiological and scientific basis for physical and cognitive rehabilitation in Parkinson’s disease;
2. Learn the different modalities of physical and cognitive rehabilitation in Parkinson’s disease reviewing the evidence from clinical trials;
3. Understand the role of neuropsychologists, exercise trainers, and physical therapists in the management of Parkinson’s disease.

Overview: Exercise, physical therapy, and benefits to the brain of Parkinson’s patients

Speaker: Lynn Rochester (UK)

Panel discussion: An active mind for a healthier life with Parkinson’s: case studies

Panelists: Lynn Rochester (UK) and Terry Ellis (USA)

Workshop: Parkinson's and Mood Changes: Depression, Apathy and Anxiety

Level of talks: Crosstalk

Learning Objectives:

1. Recognize the common behavioral changes seen in anxiety and depressive disturbances in PD;
2. List features that distinguish anxiety and depressive disturbances from healthy affective changes;
3. Identify methods to treat and manage depression, apathy, and anxiety in PD.


Overview: Depression, apathy and anxiety in Parkinson’s disease

Speaker: Laura Marsh (USA)

Panel discussion: Clinical Features and Treatment for Depression and Anxiety in Parkinson’s Disease

Panelists: Roseanne Dobkin (USA) and Laura Marsh (USA)


French Track  

(Learn more about the french track)

Level of talks: Crosstalk in French

Chair: Pierre Blanchet (Canada)

Lecture 1: Dyskinesias: Mechanism and Treatment

Speaker: Erwan Bezard (France)

Lecture 2: Parkinson’s disease is much more than a disease of dopamine

Speaker: Etienne Hirsch (France)


Roundtable: Meet the Experts

Level of talks: Crosstalk

Table 1: How can occupational therapists help manage memory challenges?

    Host: Margarita Makoutonina (Australia)

Table 2
: Motor fluctuations & dyskinesias

    Host: Joseph Jankovic (USA)

Table 3
: Speech and PD

    Host: Angie Roberts-South (Canada)

Table 4:
Non-motor Symptoms & PD

    Host: Ray Chaudhuri (UK)

Table 5:
Issues specific to Adolescents of Parents with Parkinson's

    Host: Elaine Book (Canada)

Table 6: What are animal models, why are they important in PD research and what are the challenges of using them?

    Host: Marie-Francoise Chesselet (USA)

Table 7: Parkinson’s disease and cancer

    Host: Rivka Inzelberg (Israel)

Table 8:
Open Discussion on Parkinson’s disease and the WPC

    Co-hosts: Stanley Fahn (USA) & Jon Stoessl (Canada)

Table 9:
Deep Brain Stimulation

   Host: Michael Okun (USA)


Wrap-Up: 5:15PM – 6:30PM

Facilitator: David Iverson (USA)

Panelists: Terry Ellis (USA), Eduardo Tolosa (Spain), Howard Federoff (USA), Blair Ford (USA), Kailash Bhatia (UK)

Membership Management Software Powered by YourMembership  ::  Legal